Wednesday, May 29, 2019 - Today Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Aubrey de Grey, Ph.D., CSO, SENS Research Foundation; VP of New Technology Discovery, AgeX Therapeutics, Inc., at the 6th Aging Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019, Basel, Switzerland.
People are living longer than they used to - no longer because of reductions in child mortality, but because we are postponing the ill-health of old age. Regenerative medicine and other new biomedical technologies will eventually be so comprehensive that people will stay truly youthful however long they live - which means they may mostly live very long indeed. The social and economic consequences of this transition will pervade every aspect of people's lives. The presentation will focus on the biological and sociological aspects of what will be the most momentous advance in the history of civilisation.
"It's a great pleasure to be coming to Basel for this excellent forum at Basel Life. The pharma industry is finally starting to appreciate that the medical control of aging is foreseeable, and investment in this new sector is exploding. Switzerland, as a world leader in drug discovery, is a perfect place for a forum like this," said Aubrey de Grey, Ph.D., CSO, SENS Research Foundation; VP of New Technology Discovery, AgeX Therapeutics, Inc.
"I am really excited that Aubrey de Grey is joining us. Aubrey is somewhat of a rebel in the aging field, but his long standing focus on applicable interventions targeting the fundamental processes of aging is becoming increasingly pertinent. I am therefore very happy and honored that Aubrey will travel to Basel for our meeting., " said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
"Over the last 5 years, the "Aging & Drug Discovery" and "AI for Healthcare" forums have been leading events at BaselLife, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled "the 6th Aging, AI and Drug Discovery Forum" to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet," said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019.
"The 6th annual Aging Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in aging and longevity research covering the theory, applications and convergence of these three exciting areas," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 6th Aging Research for Drug Discovery Forum Basel will bring together leaders in the aging, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. The Forum will be held in Basel, Switzerland, September 10-12, 2019.
For further information, images or interviews, please contact: Ola Popova email@example.com
About Aubrey de Grey
Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world's highest-impact peer-reviewed journal focused on intervention in aging.
He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.
About SENS Research Foundation
SENS Research Foundation's strategy to prevent and reverse age-related ill-health is to apply the principles of regenerative medicine to repair the damage of aging at the level where it occurs. We are developing a new kind of medicine: regenerative therapies that remove, repair, replace, or render harmless the cellular and molecular damage that has accumulated in our tissues with time. By reconstructing the structured order of the living machinery of our tissues, these rejuvenation biotechnologies will restore the normal functioning of the body's cells and essential biomolecules, returning aging tissues to health and bringing back the body's youthful vigor.
Official website: https:/
About AgeX Therapeutics
AgeX Therapeutics, Inc. is a biotechnology company founded in 2017 by world-leading gerontologist and bioentrepreneur Dr. Michael D. West, Ph.D., who has dedicated his life to the pursuit of understanding nature's secrets of human aging. The mission of AgeX is to develop and commercialize novel therapeutics targeting biological aging based on an emerging understanding of the 'clockwork mechanisms' of human aging. AgeX plans to apply these technologies in the practice of human medicine to extend human health and life spans.
Official website: https:/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University - to quote the University Statute - is to 'conduct research and provide further education to the highest academic level'. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.
University Website: http://introduction.
About Basel Life 2019
Aging Research for Drug Discovery Forum description
In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet.
Conference Official Website: https:/